Biotechnology Assets S.A. (BST) - Total Liabilities
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has total liabilities worth €7.01 Million EUR (≈ $8.19 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Biotechnology Assets S.A. annual equity growth to track the company's year-over-year net asset growth rate.
Biotechnology Assets S.A. - Total Liabilities Trend (2010–2024)
This chart illustrates how Biotechnology Assets S.A.'s total liabilities have evolved over time, based on quarterly financial data. See Biotechnology Assets S.A. (BST) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Biotechnology Assets S.A. Competitors by Total Liabilities
The table below lists competitors of Biotechnology Assets S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunrise New Energy Co. Ltd
NASDAQ:EPOW
|
USA | $150.12 Million |
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
USA | $9.93 Million |
|
Sejoong Co. Ltd
KQ:039310
|
Korea | ₩15.13 Billion |
|
Scienture Holdings, Inc.
NASDAQ:SCNX
|
USA | $13.84 Billion |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IS:SAMAT
|
Turkey | TL155.52 Million |
|
Winhitech Co Ltd
KQ:192390
|
Korea | ₩80.46 Billion |
|
Volt Carbon Technologies Inc
V:VCT
|
Canada | CA$1.62 Million |
|
Xinyuan Real Estate Co Ltd
NYSE:XIN
|
USA | $4.97 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Biotechnology Assets S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biotechnology Assets S.A. (BST) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotechnology Assets S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotechnology Assets S.A. (2010–2024)
The table below shows the annual total liabilities of Biotechnology Assets S.A. from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €8.17 Million ≈ $9.56 Million |
-18.87% |
| 2023-12-31 | €10.08 Million ≈ $11.78 Million |
-30.99% |
| 2022-12-31 | €14.60 Million ≈ $17.07 Million |
-6.02% |
| 2021-12-31 | €15.54 Million ≈ $18.16 Million |
-5.08% |
| 2020-12-31 | €16.37 Million ≈ $19.14 Million |
-80.77% |
| 2019-12-31 | €85.11 Million ≈ $99.50 Million |
+46.62% |
| 2018-12-31 | €58.04 Million ≈ $67.86 Million |
+507.37% |
| 2017-12-31 | €9.56 Million ≈ $11.17 Million |
+19.22% |
| 2016-12-31 | €8.02 Million ≈ $9.37 Million |
+10.90% |
| 2015-12-31 | €7.23 Million ≈ $8.45 Million |
+3.17% |
| 2014-12-31 | €7.01 Million ≈ $8.19 Million |
+40.00% |
| 2013-12-31 | €5.00 Million ≈ $5.85 Million |
+5.20% |
| 2012-12-31 | €4.76 Million ≈ $5.56 Million |
+1.37% |
| 2011-12-31 | €4.69 Million ≈ $5.49 Million |
+65.30% |
| 2010-12-31 | €2.84 Million ≈ $3.32 Million |
-- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more